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Objectives: The aim of this survey was to describe the current status of HIV care in the countries of Central
and Eastern Europe and to investigate how close the region is to achieving the UNAIDS 2020 target of 90–
90–90.
Methods: In 2014, data were collected from 24 Central and Eastern European countries using a 38-item
questionnaire.
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Results: All countries reported mandatory screening of blood and organ donors for HIV. Other groups
subjected to targeted screening included people who inject drugs (PWID) (15/24, 62.5%), men who have
sex with men (MSM) (14/24, 58.3%), and sex workers (12/24, 50.0%). Only 14 of the 24 countries (58.3%)
screened pregnant women. The percentages of late presentation and advanced disease were 40.3% (range
14–80%) and 25.4% (range 9–50%), respectively. There was no difference between countries categorized
by income or by region in terms of the percentages of persons presenting late or with advanced disease.
The availability of newer antiretroviral drugs (rilpivirine, etravirine, darunavir, maraviroc, raltegravir,
dolutegravir) tended to be signiﬁcantly better with a higher country income status. Ten countries
reported initiating antiretroviral therapy (ART) regardless of CD4+ T cell count (41.7%), ﬁve countries
(20.8%) used the threshold of <500 cells/ml, and nine countries (37.5%) used the threshold of <350 cells/
ml. Initiation of ART regardless of the CD4+ T cell count was signiﬁcantly more common among high-
income countries than among upper-middle-income and lower-middle-income countries (100% vs. 27.3%
and 0%, respectively; p = 0.001). Drugs were provided free of charge in all countries and mostly provided
by governments. There were signiﬁcant discrepancies between countries regarding the follow-up of
people living with HIV.
Conclusions: There are major disparities in the provision of HIV care among sub-regions in Europe, which
should be addressed. More attention in terms of funding, knowledge and experience sharing, and
capacity building is required for the resource-limited settings of Central and Eastern Europe. The exact
needs should be deﬁned and services scaled up in order to achieve a standard level of care and provide an
adequate and sustainable response to the HIV epidemic in this region.
© 2018 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
The scaling up of HIV-related prevention programmes and wider
availability of antiretroviral therapy (ART) have resulted in signiﬁ-
cant improvements in the global epidemiology of HIV infection. New
HIV infections have fallen globally by 16% since 2010 and AIDS-
related deaths by 48% since the peak in 2005 (UNAIDS Data, 2017).
However, speciﬁc regions in the world continue to maintain an
increasing trend. In 2016, a total of 160 453 new HIV diagnoses were
reported from 50 out of 53 countries in the World Health
Organization (WHO) European Region, corresponding to a rate of
18.2 per 100 000 population, continuing the increasing trend
(European Centre for Disease Prevention and Control/WHO Regional
Ofﬁce for Europe, 2017). The contributions of Central and Western
Europe were small (4% and 17%, respectively) compared to Eastern
Europe, where the reported cases accounted for 80% of the total new
HIV diagnoses in 2016 (European Centre for Disease Prevention and
Control/WHO Regional Ofﬁce for Europe, 2017). The incidence was
highest in Eastern Europe (50.2 per 100 000 population), followed by
Western (6.2 per 100 000) and Central (2.9 per 100 000) Europe
(European Centre for Disease Prevention and Control/WHO Regional
Ofﬁce for Europe, 2017).
The Joint United Nations Programme on HIV/AIDS (UNAIDS)
90–90–90 target requires early diagnosis, timely linkage to care,
early and uninterrupted access to treatment, strong health
systems, and the mobilization of national resources by countries
to fast-track the response to HIV infection (UNAIDS, 2014).
However, reports indicate that the HIV epidemic in the European
region is diverse, with substantial differences between Western
European countries (which seem to have reached a high standard
in HIV care) and Central and Eastern European countries, and that
this region bears many challenges in terms of patient management
and control of the epidemic (Mussini et al., 2016; Gökengin et al.,
2016; Kowalska et al., 2016; Lazarus et al., 2016).
The aim of this article is to describe the current status of HIV
care in the countries of Central and Eastern Europe, where accurate
data are lacking, and to investigate how close the region is to
achieving the UNAIDS 2020 target.
Methods
In 2014, a 38-item questionnaire on HIV care and patient
management was developed by three of the authors (DenizGökengin, Cristiana Oprea, and Josip Begovac). The WHO deﬁnition
of Central and Eastern Europe was used to select the countries for
inclusion in the survey. The WHO HIV/AIDS surveillance deﬁnition
includes 15 countries in Central Europe: Albania, Bosnia and
Herzegovina, Bulgaria*, Croatia*, Cyprus*, the Czech Republic*,
Hungary*, the former Yugoslav Republic (FYR) of Macedonia,
Montenegro, Poland*, Romania*, Serbia, Slovak Republic*,
Slovenia*, and Turkey; and includes 15 countries in Eastern
Europe: Armenia, Azerbaijan, Belarus, Estonia*, Georgia,
Kazakhstan, Kyrgyz Republic, Latvia*, Lithuania*, Moldova, Russian
Federation, Tajikistan, Turkmenistan, Ukraine, and Uzbekistan
(European Centre for Disease Prevention and Control and World
Health Organization, 2009). This list includes European Union (EU)
members (marked with an asterisk) and non-EU countries.
Although not stated in the WHO deﬁnition, Kosovo was also
included in the survey as an independent country.
For each country, one or two healthcare providers who care
for HIV patients and/or national AIDS surveillance ofﬁcers were
contacted and were invited to join the survey in September
2014. Participants who accepted were asked to complete the
questionnaire providing their national data, policies, and
implementations on HIV care. In 2015, after the change in
major antiretroviral treatment guidelines (European AIDS
Clinical Society (EACS), Department of Helath and Human
Sciences (DHHS) and WHO) to recommend the initiation of ART
regardless of the patient's CD4+ T cell count, the survey
respondents were asked to review and edit their data regarding
the criteria for ART initiation in case they had changed. They
were also asked to provide the latest list of antiretroviral drugs
that were available in their countries in 2015.
Statistical analyses
The data were described using frequencies and percentages.
Fisher’s exact test was used to compare categorical variables
between regions. The exact Chi-square test for trends was used to
compare the different categorical variables of income levels (high-
income, upper-middle-income, and lower-middle-income coun-
tries), and Fisher’s exact test was used for the comparison of
regions (Eastern and Central Europe). Percentages of late and
advanced presentation to care were compared across regions and
income levels with the exact Mann–Whitney test and exact
Kruskal–Wallis test. Analyses were performed using SAS version
Table 2
Main routes of HIV transmission by country.
Injecting drug use Heterosexual contact Sex between men
Azerbaijan Albania Czech Republic
Georgia Armenia Serbia
Kazakhstan Bosnia and Herzegovina Slovenia
Kyrgyz Republic Kosovo Hungary
Russian Federation Estonia Slovak Republic
Moldova FYR of Macedonia
Romania Bulgaria
Turkey Montenegro
Uzbekistan Croatia
Poland
FYR, Former Yugoslav Republic.
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statistically signiﬁcant.
Results
Twenty-four countries (Albania, Armenia, Azerbaijan, Bosnia
and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia,
Georgia, Hungary, Kazakhstan, Kosovo, Kyrgyz Republic, FYR of
Macedonia, Moldova, Montenegro, Poland, Romania, Russian
Federation, Serbia, Slovak Republic, Slovenia, Turkey, and Uzbeki-
stan) out of 31 (77.4%) responded to the invitation and were
included in the survey. No contact person was available in Cyprus,
Belarus, Latvia, Lithuania, Tajikistan, Turkmenistan, and Ukraine.
The countries were classiﬁed as lower-middle-income (Armenia,
Kosovo, Kyrgyz Republic, Moldova, and Uzbekistan), upper-
middle-income (Albania, Azerbaijan, Bosnia and Herzegovina,
Bulgaria, Georgia, Kazakhstan, FYR of Macedonia, Montenegro,
Romania, Serbia, and Turkey), and high-income (Croatia, Czech
Republic, Estonia, Hungary, Poland, Russian Federation, Slovak
Republic, and Slovenia) according to the World Bank deﬁnitions in
2014 (Countries and Economies, 2014)
The earliest date of the ﬁrst reported case was 1985 for seven
countries (Serbia, Romania, Czech Republic, Slovak Republic,
Croatia, Poland, and Turkey) and the latest date was 1993 for
Albania.
The cumulative number of reported HIV-positive cases as of
December 2014 is shown in Table 1.
The major route of transmission was sex between men (41.7%,
10/24 countries), followed by heterosexual contact (37.5%, 9/24
countries) and injecting drug use (20.8%, 5/24 countries) (Table 2).
All countries reported mandatory screening of blood and organ
donors for HIV. Other groups subjected to targeted screening
included people who inject drugs (PWID) (15/24, 62.5%), men who
have sex with men (MSM) (14/24, 58.3%), and sex workers (12/24,
50.0%). Other targeted HIV screening approaches were mandatory
premarital screening (Turkey, Romania, and Azerbaijan), screening
of patients with sexually transmitted infections (RussianTable 1
Cumulative number of reported HIV cases as of December 2014.
Country Populationa Cumulative 
Kosovo 1 812 771 100 
Montenegro 621 810 175 
FYR of Macedonia 2 075 625 217 
Bosnia and Herzegovina 3 817 554 272 
Slovenia 2 061 980 733 
Slovak Republic 5 418 649 811 
Albania 2 893 654 870 
Croatia 4 238 389 1325 
Armenia 3 006 154 1953 
Bulgaria 7 223 938 2043 
Serbia 7 130 576 2263 
Hungary 9 866 468 2574 
Czech Republic 10 525 347 2745 
Georgia 3 727 000 4695 
Azerbaijan 9 535 079 5439 
Kyrgyz Republic 5 835 500 5760 
Estonia 1 315 944 9260 
Moldova 3 556 397 9389 
Turkey 77 523 778 10 475 
Poland 38 011 735 17 981 
Romania 19 832 389 20 646 
Kazakhstan 17 286 224 25 444 
Uzbekistan 30 757 700 30 184 
Russian Federation 143 819 569 913 035 
FYR, Former Yugoslav Republic.
a World Bank report for 2014.
b Cumulative number reported by the end of 2014.Federation and Romania), tuberculosis (Turkey, Albania, and
Romania) and hepatitis B and C (Albania), HIV screening prior to
major surgery (Turkey), and screening of immigrants (Kyrgyz
Republic and Uzbekistan).
Pregnant women were screened in 14 of the 24 countries
(58.3%), once or twice during pregnancy. Testing was not
mandatory for pregnant women in Albania, Bosnia and Herzego-
vina, Croatia, Estonia, Hungary, FYR of Macedonia, Montenegro,
Serbia, Slovenia, and Turkey.
There was no difference between countries in terms of
screening strategies when compared according to income levels
and regions (Supplementary material, Tables S1 and S2).
Eighteen countries (75.0%) provided data for the estimated
percentage of cases with late HIV disease (CD4+ Tcell count <350/ml
or AIDS-deﬁning illness regardless of CD4+ T cell count) and 19
countries (79.2%) for advanced HIV disease (CD4+ Tcell count <200/
ml or AIDS-deﬁning illness regardless of CD4+ Tcell count). The mean
percentages of late and advanced HIV disease were 40.3% (range 14–
80%) and 25.4% (range 9–50%), respectively (Figure 1). There was no
difference between countries categorized by income or by region in
terms of the percentages of persons presenting late or with advanced
disease (Supplementary material, Tables S1 and S2).number of reported HIV casesb Beneﬁciary of the Global Fund
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Figure 1. Estimated percentage of cases diagnosed with late* and advanced**
disease in 2014. Montenegro, Estonia, Moldova, Armenia, and Azerbaijan had no
data. Kosovo reported only cases with advanced disease.
*Late disease: CD4+ T cell count <350/ml or AIDS-deﬁning illness regardless of CD4+
T cell count.
**Advanced disease: CD4+ T cell count <200/ml or AIDS-deﬁning illness regardless
of CD4+ T cell count.
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common AIDS-deﬁning illness in 2014, which was tuberculo-
sis (45.8%), followed by Pneumocystis jirovecii pneumonia
(36.0%).
Nineteen (79.2%) countries reported having national guide-
lines. The ﬁrst country to develop national guidelines was the
Russian Federation in 1994 and the latest country was Armenia in
2014. Eight countries (Albania, Bulgaria, Czech Republic, Georgia,
Kyrgyz Republic, Romania, Uzbekistan, and Russian Federation)
reported involving community and infectious diseases specialists
in the development of their national guidelines. All countries
except Slovenia and Montenegro, which did not provide data,
reported that clinicians were totally adherent to recommenda-
tions in the guidelines. Countries reported updating their national
guidelines annually (25.0%), every 2 years (25.0%), every 5 years
(18.8%), every 4 years (6.5%), and as needed (0.04%); guidelines
have not been updated in FYR of Macedonia or Turkey. CountriesTable 3
Number of HIV centres, availability of speciﬁc clinics for women, and additional suppo
Country Number of HIV centres Speciﬁc clinics for w
Kosovo 1 No 
Montenegro 1 No 
FYR of Macedonia 1 No 
Bosnia and Herzegovina 3 No 
Slovenia 1 No 
Slovak Republic 5 No 
Albania 1 No 
Croatia 1 No 
Armenia 1 No 
Bulgaria 5 No 
Serbia 4 No 
Hungary 4 Yes 
Czech Republic 7 Yes 
Georgia 5 No 
Azerbaijan 2 No 
Kyrgyz Republic 9 No 
Estonia 5 No 
Moldova 5 No 
Turkey 35 No 
Poland 14 Yes 
Romania 9 No 
Kazakhstan 22 No 
Uzbekistan 15 No 
Russian Federation 90 No 
FYR, Former Yugoslav Republic.without national guidelines reported using EACS (85.7%) and
DHHS (14.3%) guidelines.
The Russian Federation and Turkey had the highest numbers of
HIV clinics (90 and 35, respectively). Only Hungary, Czech Republic,
and Poland had speciﬁc clinics for HIV-positive women. The
availability of additional support for people living with HIV
(PLWHIV), such as psychological, diet and nutrition, and peer
support, showed variations among countries (Table 3).
Antiretroviral drug availability in Central and Eastern Europe in
2015 is shown in Table 4. The availability of many drugs,
particularly the newer antiretroviral drugs (rilpivirine, etravirine,
darunavir, maraviroc, raltegravir, and dolutegravir), tended to be
signiﬁcantly better in the countries with a higher income status
(Table 4). All countries had at least one double ﬁxed-dose
combination. Armenia and Serbia had only one ﬁxed-dose
combination (tenofovir disoproxil fumarate/emtricitabine (TDF/
FTC) and zidovudine/lamivudine (ZDV/3TC), respectively). Three-
or four-drug ﬁxed-dose combinations were not available in any
low-income country or in several upper-middle-income countries
(Romania, Albania, and Serbia).
Ten countries out of 24 reported initiating ART regardless of
CD4+ T cell count (41.7%). The ART initiation threshold was <500
cells/ml in ﬁve of the countries (5/24, 20.8%) and <350 cells/ml in
nine of the countries (9/24, 37.5%) (Table 5). The initiation of ART
regardless of the CD4+ T cell count was signiﬁcantly more common
among high-income countries than among upper-middle-income
and lower-middle-income countries (100% vs. 27.3% and 0%,
respectively; p = 0.001).
First-line therapies such as tenofovir + emtricitabine + rilpivir-
ine, tenofovir + emtricitabine + darunavir/ritonavir, abacavir +
emtricitabine + darunavir/ritonavir, and raltegravir-based initial
ART tended to be more frequently given in countries with a higher
income than in those with a lower income (Table 6). In contrast,
countries with a lower income tended to use tenofovir + emtrici-
tabine + efavirenz as ﬁrst-line therapy more frequently than higher
income countries (Table 6).
Drugs were provided free of charge in all countries. In the great
majority of countries (17/24, 70.8%), they were provided byrt available for people living with HIV according to the country.
omen Additional support
Psychological Diet and nutrition Peer counselling
Yes Yes Yes
Yes No Yes
Yes No Yes
Yes Yes Yes
Yes Yes Yes
Yes No No
Yes No Yes
Yes Yes Yes
Yes Yes Yes
Yes Yes Yes
Yes Yes Yes
Yes Yes Yes
Yes No Yes
Yes No Yes
Yes Yes Yes
Yes Yes Yes
Yes Yes Yes
Yes Yes Yes
Yes No Yes
Yes Yes Yes
Yes Yes Yes
Yes Yes Yes
Yes Yes Yes
Yes Yes Yes
Table 4
Antiretroviral drug availability in 24 countries in Central and Eastern Europe in 2015.
Variables High income
n = 8 (%)
Upper-middle income
n = 11 (%)
Lower-middle income
n = 5 (%)
Total
n = 24 (%)a
p-Value
Zidovudine, yes 8 (100.0) 11 (100.0) 3 (60.0) 22 (91.7) 0.036
Lamivudine, yes 8 (100.0) 11 (100.0) 3 (60.0) 22 (91.7) 0.036
Stavudine, yes 4 (50.0) 3 (27.3) 0 (0.0) 7 (29.2) 0.071
Didanosine, yes 4 (50.0) 6 (54.5) 0 (0.0) 10 (41.7) 0.165
Abacavir, yes 8 (100.0) 10 (90.9) 4 (80.0) 22 (91.7) 0.337
Tenofovir, yes 6 (75.0) 10 (90.9) 4 (80.0) 20 (83.3) >0.99
Emtricitabine, yes 5 (62.5) 7 (63.6) 4 (80.0) 16 (66.7) 0.772
Nevirapine, yes 6 (75.0) 11 (100.0) 4 (80.0) 21 (87.5) 0.701
Nevirapine extended release, yes 1 (12.5) 0 (0.0) 1 (20.0) 2 (8.3) >0.99
Efavirenz, yes 7 (87.5) 11 (100.0) 4 (80.0) 22 (91.7) >0.99
Rilpivirine, yes 6 (75.0) 2 (18.2) 0 (0.0) 8 (33.3) 0.005
Etravirine, yes 6 (75.0) 4 (36.4) 0 (0.0) 10 (41.7) 0.009
Atazanavir, yes 6 (75.0) 6 (54.5) 1 (20.0) 13 (54.2) 0.094
Fosamprenavir, yes 5 (62.5) 3 (27.3) 0 (0.0) 8 (33.3) 0.036
Lopinavir/ritonavir, yes 8 (100.0) 10 (90.9) 5 (100.0) 23 (95.8) >0.99
Darunavir, yes 8 (100.0) 9 (81.8) 2 (40.0) 19 (79.2) 0.017
Darunavir/cobicistat, yes 4 (50.0) 0 (0.0) 0 (0.0) 4 (16.7) 0.017
Tipranavir, yes 3 (37.5) 1 (9.1) 0 (0.0) 4 (16.7) 0.135
Ritonavir, yes 7 (87.5) 10 (90.9) 2 (40.0) 19 (79.2) 0.094
Raltegravir, yes 8 (100.0) 9 (81.8) 0 (0.0) 17 (70.8) <0.001
Dolutegravir, yes 7 (87.5) 4 (36.4) 1 (20.0) 12 (50.0) 0.023
Maraviroc, yes 7 (87.5) 3 (27.3) 0 (0.0) 10 (41.7) 0.001
Enfuvirtide 4 (50.0) 1 (9.1) 0 (0.0) 5 (20.8) 0.035
Zidovudine/lamivudine, yes 7 (87.5) 11 (100.0) 4 (80.0) 22 (91.7) >0.99
Abacavir/lamivudine/zidovudine, yes 3 (37.5) 3 (27.3) 1 (20.0) 7 (29.2) 0.559
Tenofovir DF/emtricitabine, yes 8 (100.0) 9 (81.8) 5 (100.0) 22 (91.7) >0.99
Abacavir/lamivudine, yes 7 (87.5) 7 (63.6) 2 (40.0) 16 (66.7) 0.141
Tenofovir DF/emtricitabine/efavirenz, yes 1 (12.5) 4 (36.4) 3 (60.0) 8 (33.3) 0.141
Tenofovir DF/emtricitabine/rilpivirine, yes 5 (62.5) 1 (10.0)b 0 (0.0) 6 (25.0) 0.008
Tenofovir DF/emtricitabine/cobicistat/elvitegravir, yes 3 (37.5) 0 (0.0)b 0 (0.0)c 5 (20.8) 0.039
Abacavir/lamivudine/dolutegravir, yes 4 (50.0) 1 (9.1) 0 (0.0) 5 (20.8) 0.039
Tenofovir DF = tenofovir disoproxil fumarate.
a n = 23 for tenofovir DF/emtricitabine/rilpivirine and abacavir/lamivudine/dolutegravir, n = 22 for tenofovir DF/emtricitabine/cobicistat/elvitegravir. Azerbaijan did not
provide data for the combinations of tenofovir DF/emtricitabine/rilpivirine, tenofovir DF/emtricitabine/cobicistat/elvitegravir, and abacavir/lamivudine/dolutegravir and
Armenia did not provide data on tenofovir DF/emtricitabine/cobicistat/elvitegravir.
b n = 10.
c n = 4.
Table 5
Antiretroviral treatment initiation threshold for CD4+ T cell count according to
country income (as of 2015, after the change in major guidelines).
Income CD4+ T cells
<350/ml <500/ml Any
Lower-
middle
Kosovo Armenia Georgia
Uzbekistan Kyrgyz Republic
Moldova
Upper-
middle
Albania Bosnia and Herzegovina Turkey
Azerbaijan Kazakhstan Romania
Bulgaria
FYR of Macedonia
Montenegro
Serbia
High Russian Federation Croatia
Czech Republic
Estonia
Hungary
Poland
Slovak Republic
Slovenia
Total 9/24 (37.5%) 5/24 (20.8%) 10/24 (41.7%)
FYR, Former Yugoslav Republic.
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tional funds (4/24, 16.7%) and international funds and government
(3/24, 12.5%). More than half of the countries (13/24, 54.2%)
reported being a beneﬁciary of the Global Fund to Fight AIDS,
Tuberculosis and Malaria. Signiﬁcantly more lower-incomecountries (5/5, 100%) and upper-middle-income countries (8/11,
72.7%) were beneﬁciaries of the Global Fund compared to high-
income countries (0/8, p < 0.001).
Stock-outs were reported by nine of 23 countries (39.1%);
Azerbaijan did not provide any data for stock-outs. Three countries
had stock-outs once a year and one country had stock-outs twice a
year. Five countries experienced stock-outs very rarely.
The frequencies of testing for HIV RNA, CD4+ T cell count, and
biochemical parameters are shown in Table 7.
Thirteen countries (Slovenia, Romania, Czech Republic,
Bulgaria, Croatia, Bosnia and Herzegovina, Georgia, Estonia,
Moldova, Uzbekistan, Kazakhstan, Russian Federation, and
Armenia) reported data for the HIV continuum of care analysis
for 2014. There were signiﬁcant variations between countries in
terms of the methodologies used for calculations of the elements of
continuum of care. Therefore the results given here are not
comparable with each other. Nine countries (Armenia, Czech
Republic, Estonia, Georgia, Moldova, Kazakhstan, Romania, Russian
Federation, and Uzbekistan) used the UNAIDS tool ‘Spectrum’ as an
estimation method (Anon, 2016a). Slovenia made a rough
estimation. Croatia used the European Centres for Disease
Prevention and Control (ECDC) tool (Anon, 2015) and Bosnia
and Herzegovina used the total reported number of PLWHIV.
Estonia and Moldova did not report the deﬁnition of undetectable
HIV RNA. The cut-off for undetectable viral load was <20 copies/ml
for Slovenia and Czech Republic, <40 copies/ml for Bulgaria and
Bosnia and Herzegovina, <50 copies/ml for Kazakhstan, Serbia,
Romania, and the Russian Federation, <250 copies/ml for Armenia,
<400 copies/ml for Croatia, <500 copies/ml for Uzbekistan, and
Table 6
First-line combinations in 22 countries of Eastern and Central Europe, 2014.
First-line combination High income countries
n = 8 (%)
Upper-middle income countries
n = 10 (%)
Lower-middle income countries
n = 4 (%)
Total
n = 22 (%)
p-Value
Non-nucleoside analogue combinations
Tenofovir + emtricitabine + efavirenz 2 (25.0) 9 (81.8)a 4 (100.0) 15 (68.2) 0.004
Abacavir + lamivudine + efavirenz 3 (37.5) 2 (20.0) 0 (0.0) 5 (22.7) 0.182
Zidovudine + lamivudine + efavirenz 0 (0.0) 4 (40.0) 2 (50.0) 6 (27.3) 0.053
Tenofovir + emtricitabine + rilpivirine 5 (62.5) 0 (0.0) 0 (0.0) 5 (22.7) 0.003
Abacavir + lamivudine + rilpivirine 4 (50.0) 0 (0.0) 0 (0.0) 4 (18.2) 0.015
Tenofovir + emtricitabine + nevirapine 1 (12.5) 1 (10.0) 2 (50.0) 4 (18.2) 0.264
Abacavir + lamivudine + nevirapine 1 (12.5) 0 (0.0) 0 (0.0) 1 (4.5) 0.546
Zidovudine + lamivudine + nevirapine 0 (0.0) 1 (10.0) 2 (50.0) 3 (13.6) 0.042
Protease inhibitor combinations
Tenofovir + emtricitabine + darunavir/r 6 (75.0) 2 (20.0) 0 (0.0) 8 (36.4) 0.005
Abacavir + lamivudine + darunavir/r 6 (75.0) 2 (20.0) 0 (0.0) 8 (36.4) 0.005
Tenofovir + emtricitabine + lopinavir/r 2 (25.0) 2 (20.0) 0 (0.0) 4 (18.2) 0.467
Abacavir + lamivudine + lopinavir/r 2 (25.0) 2 (20.0) 0 (0.0) 4 (18.2) 0.467
Tenofovir + emtricitabine + atazanavir/r 2 (25.0) 1 (10.0) 0 (0.0) 3 (13.6) 0.408
Abacavir + lamivudine + atazanavir/r 2 (25.0) 1 (10.0) 0 (0.0) 3 (13.6) 0.408
Zidovudine + lamivudine + atazanavir/r 1 (12.5) 0 (0.0) 0 (0.0) 1 (4.5) 0.546
Integrase inhibitor combinations
Tenofovir + emtricitabine + raltegravir 4 (50.0) 1 (10.0) 0 (0.0) 5 (22.7) 0.036
Abacavir + lamivudine + raltegravir 4 (50.0) 1 (10.0) 0 (0.0) 5 (22.7) 0.036
Tenofovir + emtricitabine + dolutegravir 3 (37.5) 1 (10.0) 0 (0.0) 4 (18.2) 0.133
Abacavir + lamivudine + dolutegravir 3 (37.5) 1 (10.0) 0 (0.0) 4 (18.2) 0.133
Tenofovir + emtricitabine + cobicistat + elvitegravir 3 (37.5) 0 (0.0) 0 (0.0) 3 (13.6) 0.078
a For tenofovir/emtricitabine/efavirenz the number of responding countries is 23. Armenia did not provide data for this table.
Table 7
HIV RNA and CD4+ T cell testing frequency and routine follow-up testing.
Patients not on ART CD4+ T cells
Twice a year 50.0%
Every 3 months 25.0%
Every 4 months 20.8%
Once a year 4.2% (Albania)
HIV RNA
Twice a year 45.8%
Every 3 months 20.8%
Every 4 months 20.8%
Once a year 12.5% (Russian Federation, Uzbekistan, Albania)
Patients who have recently initiated ART CD4+ T cells
First month, then every 3 months 45.8%
Twice a year 20.8%
Every 3 months 20.8%
Every 4 months 12.5%
HIV RNA
First month, then every 3 months 37.5%
Twice a year 20.8%
Every 4 months 20.8%
Every 3 months 16.7%
Once a year 4.2% (Albania)
Patients stable on ART CD4+ T cells
Twice a year 60.9%
Every 4 months 17.4%
Once a year 13.0%
Every 3 months 8.7%
HIV RNA
Twice a year 73.9%
Once a year 13.0%
Every 4 months 8.7%
Every 3 months 4.3%
Routine follow-up testing
Test Countries that run the test/calculation (%)
eGFR 47.8
Framingham score 43.5
Liver function tests 100.0
Renal function tests 95.8a
Glucose 100.0
Vitamin D 30.4
ART, antiretroviral therapy; eGFR, estimated glomerular ﬁltration rate.
a Montenegro reported no regular testing for renal function.
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Table 8
Data reported from Central and Eastern European countries on the continuum of care for HIV for 2014.a,b
Armenia Georgia Moldova Uzbekistan Kazakhstan Estonia Russia Bulgaria Romania Bosnia and
Herzegovina
Slovenia Croatia Czech Republic
PLWHIV 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
Diagnosed 39% 56% 38% 52% 85% 85% 78% 64% 98% 77% 58% 76% 51%
Linked to
care
33% 41% 17% 25% 51% 58% 31% 88% 74% 53% 66% 31%
On ART 19% 34% 23% 25% 32% 19% 23% 87% 53% 50% 62% 31%
Undetectable 16% 29% 13% 16% 20% 51% 50% 48% 54% 24%
PLWHIV, people living with HIV; ART, antiretroviral therapy.
a The data are not directly comparable across countries because there were methodological differences between countries regarding the method of estimation for the
number of PLWHIV, the number of PLWHIV on ART, and the viral load cut-off deﬁnition for being undetectable.
b For the deﬁnitions and methodology used for each element of the continuum, please refer to the Methods section.
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age of undetectable HIV viral load among all PLWHIV. Of the ﬁve EU
countries, three reported having an undetectable rate close to or
above 50%, whereas among the ﬁve non-EU countries, only one
reported this percentage at 50%. Table 8 shows the elements of the
continuum for the 13 countries that provided data for the
continuum.
Seventeen countries had data for hepatitis B virus surface
antigen (HBsAg) prevalence and 18 countries for antibody to
hepatitis C virus (anti-HCV) prevalence in the HIV-infected
population. HBsAg positivity rates were lowest in Kosovo (0%)
and the Kyrgyz Republic (0.02%) and highest in Kazakhstan (30%)
and Bosnia and Herzegovina (20%), with a mean rate of 10.3% for
the whole region. Anti-HCV rates were lowest in Kosovo (0%) and
the FYR of Macedonia (1%) and highest in Azerbaijan (51.7%),
Kazakhstan (50%), the Russian Federation (48%), and Georgia (39%),
with a mean rate of 23.4% for the whole region. Estonia reported
22% prevalence for HBsAg and 71% for anti-HCV, with a note that
the data were extracted from research and did not represent
national data.
Table 9 shows the availability of drugs for hepatitis B and C in
the countries of Central and Eastern Europe. Several of the new
drugs for hepatitis C were reported to be available in Bulgaria,
Czech Republic, Georgia, Russian Federation, Slovak Republic,
Slovenia, Poland, and Turkey. Direct-acting antivirals (DAAs) were
not available in seven countries (Albania, Serbia, Kosovo, FYR of
Macedonia, Montenegro, Bosnia and Herzegovina, and
Kazakhstan).
Discussion
This appears to be the largest report on HIV care in Central and
Eastern Europe to date: the survey included approximately 80% of
the countries in the WHO deﬁned regions. The results of this study
show that there are signiﬁcant variations between countriesTable 9
Available drugs for hepatitis B and hepatitis C treatment in 23 Central and
Drugs for hepatitis B Number D
Interferon alpha 11 In
Peg-interferon alpha 17 P
Lamivudine 20 R
Emtricitabine 11 B
Telbivudine 7 S
Adefovir 6 T
Tenofovir disoproxil fumarate 17 S
Entecavir 11 D
O
S
O
a Azerbaijan reported no data for hepatitis B and hepatitis C drugs.regarding the epidemiology of HIV infection and HIV care and that
many countries in the region and especially in Eastern Europe are
far from reaching the UNAIDS 2020 goal of 90–90–90.
The data presented in the report suggest that despite efforts to
scale up testing, late diagnosis and late presentation of HIV cases
are still major problems in the region, with late presentation rates
as high as 60–80% in Bosnia and Herzegovina, Georgia, and Albania.
Furthermore, no signiﬁcant difference between regions and
income levels was found regarding late presentation rates.
Progression to AIDS and death is signiﬁcantly high among late
presenters, especially within the ﬁrst year of diagnosis (Mocroft
et al., 2013; Chadborn et al., 2006). Achieving and maintaining
undetectable viremia with ART is associated with a good prognosis
in late presenters, regardless of the CD4+ T cell count (Jevtovic
et al., 2009), underlining the importance of early diagnosis and
treatment. Almost 50% of PLWHIV in Europe were reported to be
late presenters between 2010 and 2013, ranging from >60% of
heterosexual men or people of African origin to almost 39% of MSM
and female PWID (The late presenters working group in COHERE in
EuroCoord, 2015). Even in well-established indicator conditions,
the testing rates across Europe were found to be low, with many
missed opportunities for early diagnosis (Raben et al., 2015), and
the overall late presentation rates across Europe between 2010 and
2013 did not change signiﬁcantly over time (The late presenters
working group in COHERE in EuroCoord, 2015). In addition, late
presentation rates increased between 2000 and 2011 among
female heterosexuals and male PWID in Southern Europe and in
male and female PWID in Eastern Europe (Mocroft et al., 2013).
While the ECDC reported a 58% increase in the overall number of
tests performed in the region between 2007 and 2016, the rates for
late presentation (51%) and advanced disease (30%) still remained
high in 2016 (European Centre for Disease Prevention and Control/
WHO Regional Ofﬁce for Europe, 2017).
Although the data in this report do not provide any insight into
the factors related to late presentation, they have been described in Eastern European countries for 2014.a
rugs for hepatitis C Number
terferon alpha 11
eg-interferon alpha 22
ibavirin 22
oceprevir 11
imeprevir 9
elaprevir 10
ofosbuvir 9
aclatasvir 7
mbitasvir/paritaprevir/ritonavir 8
ofosbuvir/ledipasvir 6
mbitasvir/paritaprevir/ritonavir + dasabuvir 8
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of stigma, reduced accessibility of tests, lack of focused screening
programmes for key populations, and low perception of risk
(Network of Low Prevalence Countries in Central and Southeast
Europe (NELP), 2014). The ECDC has reported that testing rates
among key populations are very low and only a few countries
report testing data for these populations (Network of Low
Prevalence Countries in Central and Southeast Europe (NELP),
2014). The lower than expected rates of targeted screening among
key populations in Central and Eastern European countries in the
present study, especially MSM and sex workers, suggests a need for
a more focused and novel approach for speciﬁc groups with a high
risk of acquiring HIV infection to remove obstacles to testing. HIV
testing is reported to be cost-effective if HIV prevalence exceeds
0.1% (Paltiel et al., 2005; Sanders et al., 2005); thus, screening of the
general population, such as premarital testing, rather than
screening of key populations in low-prevalence countries such
as Turkey and Azerbaijan, may be an unwise use of resources.
Although the rising number of new HIV diagnoses in the region
may be attributed in part to the increasing number of annual HIV
tests, a targeted screening strategy rather than screening of low-
risk populations may be a more favourable and effective approach
for achieving the UNAIDS targets.
While overall the main mode of HIV transmission seemed to be
sex between men, the major variations by geographical area is an
indicator of the diversity in the epidemiology of HIV in Europe. All
countries reporting injecting drug use as the major route of HIV
transmissionwere in Eastern Europe, all with high rates of hepatitis C
virus co-infection. The ECDC reported that the most common mode
of transmission was sexual transmission between men in the EU/
European Economic Area (EEA) and heterosexual contact and
injecting drug use in the Eastern European countries (European
Centre for Disease Prevention and Control/WHO Regional Ofﬁce for
Europe, 2017). Recent reports have suggested an increasing trend in
transmission through sex between men in the region (European
Centre for Disease Prevention and Control/WHO Regional Ofﬁce for
Europe, 2017; Gökengin et al., 2016; Pharris et al., 2015), and the
numbers for transmission through sex between men may be
underestimations due to the high stigma as well as laws and
sanctions against gay people in some countries in the region
(Eurasian Coalition, 2015; Santos et al., 2017; Takacs et al., 2013).
Almost all countries had developed national guidelines, and
those without guidelines reported the use of the two major
guidelines (EACS and DHHS). However, despite the change in the
recommendations of major guidelines following the publication of
the results of the START study (INSIGHT START Study Group et al.,
2015), i.e., to start ART in all people diagnosed with HIV regardless
of CD4+ T cell count, more than half of the countries were not able
to act fast enough to comply with this recommendation (Anon,
2017; Panel on Antiretroviral Guidelines for Adults and Adoles-
cents, 2017; Anon, 2016b). About one third of the countries still
required the patient to have a CD4+ T cell count under 350 cells/ml
before initiating ART, regardless of the recommendation in EACS,
DHHS, and WHO guidelines. All but one of these countries was a
beneﬁciary of the Global Fund, which had already ended in 2014 or
2015 or would be over by 2018. Although the scene has started to
change in Europe recently, with the number of countries initiating
treatment regardless of the CD4+ T cell count increasing from four
in 2014 to 30 in 2016, only two countries (Montenegro and Serbia)
included in the present study had changed their ART initiation
policy in agreement with the guidelines in 2016 and two other
countries (Bulgaria and Uzbekistan) increased their CD4+ T cell
threshold from <350 to <500 cells/ml (EDC Special Report, 2017;
personal communication with Teymur Noori of the ECDC). Even in
the EU/EEA, one out of six people were still not on treatment in
2016 (ECDC Special Report, 2016).Although ART was reported to be offered free of charge in all
countries, the unavailability of newer ﬁrst-line drugs with better
tolerability and lower short- and long-term toxicity, as well as the
lack of single-tablet regimens, which are associated with better
adherence in many countries, seems to be another major obstacle
for early and effective treatment of HIV infection. This was
reﬂected in the choice of treatment regimens, with high-income
countries signiﬁcantly more often choosing the regimens including
newer drugs compared to low- and middle-income countries.
Besides, although the study did not provide information on the use
of toxic drugs such as didanosine (ddI) and stavudine (d4T), their
continuing availability is alarming. It is well-established that a
simpler, less toxic treatment, with fewer drug–drug interactions, is
the key to greater uptake and better adherence, which ultimately
results in higher rates of viral suppression (Gulick, 2014; Cihlar and
Fordys, 2016).
The high prevalence of hepatitis C in Eastern European
countries correlates well with the major transmission route and
high screening rates reported by Lazarus et al. for that region
(Lazarus et al., 2016). Unfortunately, similar to the ﬁndings of
Lazarus et al., the availability of new hepatitis C drugs is low in
these countries, with few of them having access to DAAs.
The standards of HIV care require regular and close follow-up of
HIV patients. Follow-up includes both markers of HIV, such as CD4
+ T cell count and HIV RNA testing, as well as tests for comorbidities
and co-infections that may complicate HIV infection and vice-
versa. All guidelines have clear deﬁnitions for standards of HIV care
and have similar recommendations for follow-up of PLWHIV
(Anon, 2017; Panel on Antiretroviral Guidelines for Adults and
Adolescents, 2017 Although most countries reported having
national guidelines or using major guidelines, marked discrep-
ancies were noted between countries regarding the follow-up of
HIV patients.
Antiretroviral resistance testing is not a common approach in
the Eastern European region due to the unavailability of the
procedure or high costs (Kowalska et al., 2016; Lazarus et al., 2016).
Thus, the reported low frequency of HIV RNA testing in some
countries may prevent early intervention in the case of virological
failure, resulting in the development of resistant virus. In addition,
the lack of regular testing/calculations for markers of comorbid-
ities may hamper efforts for the prevention or early treatment of
major comorbidities that may occur due to the aging population of
PLWHIV or adverse effects of drugs or drug–drug interactions.
Although it is difﬁcult to comment on the continuum of care
graphics due to considerable methodological differences between
countries, the most common breakpoint in the continuum of care
seems to be between the estimated number of PLWHIV and those
who are diagnosed. While it has been rather easy to reach the ‘third
900, which is having an undetectable viral load (even in resource-
limited settings), the major obstacle is to achieve the ‘ﬁrst and
second 900, which are diagnosis and the initiation of ART (Jevtovic
et al., 2014). Also, 12 out of 24 countries could not provide any data
for the continuum of care. According to UNAIDS, out of an
estimated 1.5 million PLWHIV in Eastern Europe and Central Asia,
67% know their HIV status, 21% are on ART, and 19% are virally
suppressed (UNAIDS, 2016). Drew et al. (Drew et al., 2017) reported
that among 16 EU and non-EU countries, 77% and 45% (overall 76%)
of PLWHIV had been diagnosed, 62% and 21% (overall 60%) of those
diagnosed were on treatment, and 55% and 14% (overall 53%) of
those on treatment were virally suppressed, respectively, which
corresponds well with the present study results. The data from the
present study support the conclusions of the 2017 ECDC report on
the continuum of HIV care (Monitoring implementation of the
Dublin Declaration on Partnership to ﬁght HIV/AIDS in Europe and
Central Asia: 2017 progress report), which also stressed the high
proportion of people with HIV who did not know their status or
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non-EU countries had lower viral suppression rates among all
people estimated to be living with HIV compared to EU countries
(EDC Special Report, 2017).
A modelling study looking at the potential impact on HIV
incidence and prevalence of needle and syringe programmes
(NSP), opioid substitution therapy (OST), and ART in the Russian
Federation, Estonia, and Tajikistan, reported that even if all three
interventions were combined, reducing HIV incidence to less than
1% and prevalence to less than 20% would be very difﬁcult
(Vickerman et al., 2014).
UNAIDS announced that the pace of decline in new HIV
infections was far too slow to reach the Fast-Track Target agreed
upon by the United Nations General Assembly in 2016, which was
to reduce the number of new infections to fewer than 500 000 per
year by 2020 (UNAIDS Data, 2017). The low levels of ART coverage,
low viral suppression rates, and improper testing strategies,
combined with the low availability of NSP and OST in Eastern
European countries (Lazarus et al., 2016), imply that we are still a
long way off the set targets.
This study has some limitations, as outlined below.
(1) The questionnaire did not include all aspects of HIV care.
(2) The respondents of the survey were not randomly selected; the
responses may be biased.
(3) Only one or two HIV specialists from each country were
included in the survey, and although the questions were
intended to assess country-speciﬁc approaches to HIV care,
there may have been respondent-speciﬁc interpretations and
the data may not necessarily reﬂect the actual HIV care
approach of the country.
(4) Some data were extracted from the personal records of the
respondents or from various surveys and may not represent
national data.
(5) The comparison of small numbers may have hampered the
accuracy of statistical analyses.
(6) The time to ﬁnd contacts in each country, to start and continue
correspondence, and to collect data was very long, and some
data might have changed between the time the questionnaire
was completed and the time the manuscript was published.
Conclusions and the way forward
Many countries in this region, especially those with a low
income, are highly dependent on donor funding. However, this
support has started to fade out and national governments
will have to mobilize their local resources to compensate
for this. The right of access to affordable, tolerable, durable,
and sustainable ART regimens, as well as to prevention,
diagnosis, and treatment of comorbidities and co-infections,
is the key element for the right to health and to control the HIV
epidemic. Unfortunately, many of those elements seem to be
lacking in low-income and several middle-income countries in
the region.
There was a clear correlation between the World Bank gross
national income classiﬁcation of countries and several elements of
HIV care. Countries with a higher income had a tendency to initiate
ART earlier, had better access to novel drugs, and tended to prefer
new ﬁxed-dose formulations and new drug classes as ﬁrst-line
treatment more commonly than lower income countries. Although
all countries provided drugs free of charge, the high level of donor
dependency of lower-income and several upper-middle-income
countries may be one of the major reasons for the unavailability of
newer drug classes and drug formulations and the discrepancies
between countries regarding the regular follow-up and care of HIVpatients. Even if longer term funding is secured, many people,
mostly those in key populations, will continue to face many
obstacles to accessing HIV care and prevention, which also needs to
be addressed.
There are major disparities in the provision of HIV care among
sub-regions in Europe, which should be addressed. More attention
in terms of funding, knowledge and experience sharing, and
capacity building is required for the resource-limited settings of
Central and Eastern Europe. The exact needs should be deﬁned and
services scaled up in order to achieve a standard level of care and
provide an adequate and sustainable response to the HIV epidemic
in this region.
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